348 related articles for article (PubMed ID: 18236722)
1. Cytoprotection for radiation-associated normal tissue injury.
Mao J; Fatunase OA; Marks LB
Cancer Treat Res; 2008; 139():307-27. PubMed ID: 18236722
[No Abstract] [Full Text] [Related]
2. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
[TBL] [Abstract][Full Text] [Related]
3. Established and emerging uses of cytoprotection in head and neck cancer.
Rosenthal DI
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):129-30. PubMed ID: 16490868
[No Abstract] [Full Text] [Related]
4. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
5. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
Huang R; Yu H; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
[TBL] [Abstract][Full Text] [Related]
6. The role of amifostine as a radioprotector.
Wasserman TH; Brizel DM
Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
[TBL] [Abstract][Full Text] [Related]
7. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Boccia R
Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
[TBL] [Abstract][Full Text] [Related]
8. Radioprotective effects of amifostine.
Wasserman T
Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
[TBL] [Abstract][Full Text] [Related]
9. Proceedings of the Fourth International Cytoprotection Investigators' Congress. May 2004. Philadelphia, Pennsylvania, USA.
Semin Oncol; 2004 Dec; 31(6 Suppl 18):1-73. PubMed ID: 15801121
[No Abstract] [Full Text] [Related]
10. New approaches to preventing xerostomia.
J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
[No Abstract] [Full Text] [Related]
11. Proceedings of the 3rd International Cytoprotection Investigators' Congress. May 15-18, 2003, Nevis, West Indies.
Semin Oncol; 2003 Dec; 30(6 Suppl 18):1-108. PubMed ID: 14727234
[No Abstract] [Full Text] [Related]
12. Randomized trials of amifostine and radiotherapy: effect on survival?
Bourhis J; Thephamongkhol K; Pignon JP
Semin Oncol; 2004 Dec; 31(6 Suppl 18):62-6. PubMed ID: 15726526
[TBL] [Abstract][Full Text] [Related]
13. Radiation-induced toxicities: the role of radioprotectants.
Curran WJ
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):2-4. PubMed ID: 9794993
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer: the role of cytoprotection in treating therapy-related toxicity.
Gopal R
J Support Oncol; 2004; 2(6 Suppl 3):13-7. PubMed ID: 15605920
[TBL] [Abstract][Full Text] [Related]
15. Radiobiologic modeling of cytoprotection effects in radiotherapy.
Plataniotis GA; Dale RG
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):236-42. PubMed ID: 17448877
[TBL] [Abstract][Full Text] [Related]
16. [Radiation protectants of the crystalline lens].
Belkacémi Y; Pasquier D; Castelain B; Warnet JM; Lartigau E
Cancer Radiother; 2003 Nov; 7 Suppl 1():49s-54s. PubMed ID: 15124544
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic approaches to radiation protection.
Brizel DM
J Clin Oncol; 2007 Sep; 25(26):4084-9. PubMed ID: 17827457
[TBL] [Abstract][Full Text] [Related]
18. [Amifostine as a supporting treatment during cancer therapy].
Jantunen E; Puistola U
Duodecim; 1999; 115(11):1223-7. PubMed ID: 11877841
[No Abstract] [Full Text] [Related]
19. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
[No Abstract] [Full Text] [Related]
20. Amelioration of the pathological changes induced by radiotherapy in normal tissues.
Rezvani M
J Pharm Pharmacol; 2008 Aug; 60(8):1037-48. PubMed ID: 18644196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
